


Brusatol

Cat. No.:	HY-19543
CAS No.:	14907-98-3
Molecular Formula:	C ₂₆ H ₃₂ O ₁₁
Molecular Weight:	520.53
Target:	Keap1-Nrf2; Apoptosis
Pathway:	NF-κB; Apoptosis
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (48.03 mM; Need ultrasonic)																	
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent Concentration</th> <th rowspan="2">Mass</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>1.9211 mL</td> <td>9.6056 mL</td> <td>19.2112 mL</td> </tr> <tr> <td>5 mM</td> <td>0.3842 mL</td> <td>1.9211 mL</td> <td>3.8422 mL</td> </tr> <tr> <td>10 mM</td> <td>0.1921 mL</td> <td>0.9606 mL</td> <td>1.9211 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass	1 mg	5 mg	10 mg	1 mM	1.9211 mL	9.6056 mL	19.2112 mL	5 mM	0.3842 mL	1.9211 mL	3.8422 mL	10 mM	0.1921 mL	0.9606 mL	1.9211 mL
Solvent Concentration	Mass			1 mg	5 mg	10 mg												
		1 mM	1.9211 mL	9.6056 mL	19.2112 mL													
5 mM	0.3842 mL	1.9211 mL	3.8422 mL															
10 mM	0.1921 mL	0.9606 mL	1.9211 mL															
	Please refer to the solubility information to select the appropriate solvent.																	
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution 																	

BIOLOGICAL ACTIVITY

Description	Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent ^[1] . Brusatol increases cellular apoptosis ^[2] .
IC₅₀ & Target	Nrf2 ^[1]
In Vitro	Brusatol (0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 μg/mL) reduces the viability of CT-26 cells in a dose-dependent manner with

IC₅₀ value of 0.27±0.01µg/mL. When Brusatol is combined with Cisplatin (CDDP) at a constant concentration ratio of 1:1, cell growth inhibition is markedly enhanced compared with single-agent treatment; the IC₅₀ value of Brusatol and CDDP cotreatment is 0.19±0.02µg/mL^[2].

Brusatol provokes a rapid and transient depletion of Nrf2 protein, through a posttranscriptional mechanism, in mouse Hepa-1c1c7 hepatoma cells. Brusatol sensitizes mammalian cells to chemical toxicity^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	The murine CT-26 CRC cell line
Concentration:	0.05, 0.15, 0.45, 1.35, 4.05 and 12.15 µg/mL
Incubation Time:	48 hours
Result:	The viability of CT-26 cells was reduced in a dose-dependent manner, with IC ₅₀ value of 0.27±0.01 µg/mL.

Western Blot Analysis^[3]

Cell Line:	Mouse Hepa-1c1c7 hepatoma cells
Concentration:	1, 3, 10, 30, 100, 300, and 1000 nM
Incubation Time:	2 hours
Result:	Provoked the depletion of Nrf2, in a concentration-dependent manner within 2 h of exposure to cells.

In Vivo

Brusatol is able to reach the tumor tissue and inhibit the Nrf2 pathway. Nude mice are injected with A549 cells to induce tumor growth, followed by a single i.p. injection of 2 mg/kg Brusatol. Nrf2 protein levels are significantly decreased at 24 h or 48 h postinjection^[1].

Cisplatin (2 mg/kg) or Brusatol (2 mg/kg) alone does not inhibit tumor growth significantly, whereas in the combination group, tumor size is significantly reduced^[1]."

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice 4-6 wk old bearing A549 xenografts ^[1]
Dosage:	2 mg/kg
Administration:	Treated i.p.; Cisplatin (2 mg/kg), Brusatol (2 mg/kg), or in combination every other day for a total of five times
Result:	Nrf2 protein levels were significantly decreased at 24 h or 48 h postinjection. Cisplatin or Brusatol alone did not inhibit tumor growth significantly, whereas in the combination group, tumor size was significantly reduced. "

CUSTOMER VALIDATION

- Cell Commun Signal. 2022 Oct 27;20(1):168.
- Biomed Pharmacother. 2023 Dec 12;170:116006.
- Free Radic Biol Med. 2020 Nov 20;160:820-836.
- Antioxidants (Basel). 2023 Nov 13, 12(11), 1999.

-
- Food Funct. 2023 Oct 6.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Dongmei Ren, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8.
- [2]. Hai-Ming Chen, et al. Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Int J Mol Med. 2018 Mar;41(3):1447-1454.
- [3]. Adedamola Olayanju, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015 Jan;78:202-12.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA